Literature DB >> 12560226

Low frequency of CD94/NKG2A+ T lymphocytes in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis, but not in asymptomatic carriers.

Mineki Saito1, Veronique M Braud, Peter Goon, Emmanuel Hanon, Graham P Taylor, Akiko Saito, Nobutaka Eiraku, Yuetsu Tanaka, Koichiro Usuku, Jonathan N Weber, Mitsuhiro Osame, Charles R M Bangham.   

Abstract

Human natural killer (NK)-cell receptors are expressed by NK cells and some T cells, primarily TCR+CD8+ cytotoxic T lymphocytes (CTLs). Inhibitory NK cell receptors (iNKRs) can down-regulate antigen-mediated T-cell effector functions, including cytotoxic activity and cytokine release. In the present study we demonstrate that CD3+ T cells that bind tetramers of HLA-E and express its ligand, the NK-cell inhibitory receptor CD94/NKG2A, were significantly decreased in frequency in patients with human T-cell lymphotropic virus 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) but not in asymptomatic HTLV-1 carriers. These cells were either alphabeta or gammadelta T cells. T-cell receptor (TCR) Vbeta-specific reverse transcription-polymerase chain reaction and spectratyping analysis revealed that the TCR repertoire in directly isolated HLA-E tetramer-positive cells from peripheral blood mononuclear cells was skewed in both HTLV-1-infected and healthy individuals. However, oligoclonally or monoclonally expanded levels of TCR Vbetawere more frequently detected within HTLV-1-infected individuals than healthy controls. Importantly, HLA-E tetramer-positive or NKG2A+ T cells from HTLV-1 patients do not express Tax and display different TCR usage from the immunodominant Tax11-19-specific CD8+ T cells, suggesting that they do not encounter HTLV-1-infected cells. The expression of NK cell-associated receptors by clonally expanded CD8+ T cells during chronic viral infection suggests that these receptors play a role in regulating CD8+ T cell-mediated antiviral immune responses and that a decrease of this cell subset results in an increased risk of inflammatory diseases such as HAM/TSP.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560226     DOI: 10.1182/blood-2002-09-2855

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  13 in total

Review 1.  Neuroimmunity of HTLV-I Infection.

Authors:  Eiji Matsuura; Yoshihisa Yamano; Steven Jacobson
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-02       Impact factor: 4.147

Review 2.  Human T-lymphotropic virus type 1 (HTLV-1): persistence and immune control.

Authors:  Charles R M Bangham
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

3.  Immunogenetics and the Pathological Mechanisms of Human T-Cell Leukemia VirusType 1- (HTLV-1-)Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).

Authors:  Mineki Saito
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-02-10

4.  Differential induction of CD94 and NKG2 in CD4 helper T cells. A consequence of influenza virus infection and interferon-gamma?

Authors:  Christine M Graham; Jillian R Christensen; D Brian Thomas
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

Review 5.  How does HTLV-1 cause adult T-cell leukaemia/lymphoma (ATL)?

Authors:  Charles R M Bangham; Lee Ratner
Journal:  Curr Opin Virol       Date:  2015-09-27       Impact factor: 7.090

6.  Plasma proteome analysis in HTLV-1-associated myelopathy/tropical spastic paraparesis.

Authors:  Paul D W Kirk; Aviva Witkover; Alan Courtney; Alexandra M Lewin; Robin Wait; Michael P H Stumpf; Sylvia Richardson; Graham P Taylor; Charles R M Bangham
Journal:  Retrovirology       Date:  2011-10-12       Impact factor: 4.602

7.  Decrease of peripheral and intestinal NKG2A-positive T cells in patients with ulcerative colitis.

Authors:  Takehiko Katsurada; Waka Kobayashi; Utano Tomaru; Tomohisa Baba; Shigeru Furukawa; Akihiro Ishizu; Kazuyoshi Takeda; Naoya Sakamoto; Masahiro Asaka; Hiroshi Takeda; Masanori Kasahara
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

8.  Immunopathogenesis of human T-cell leukemia virus type-1-associated myelopathy/tropical spastic paraparesis: recent perspectives.

Authors:  Mineki Saito; Charles R M Bangham
Journal:  Leuk Res Treatment       Date:  2012-02-06

Review 9.  Neuroimmunological aspects of human T cell leukemia virus type 1-associated myelopathy/tropical spastic paraparesis.

Authors:  Mineki Saito
Journal:  J Neurovirol       Date:  2013-08-14       Impact factor: 3.739

10.  The Impact of Immune Response on HTLV-I in HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP).

Authors:  Houshang Rafatpanah; Reza Farid Hosseini; Seyed Hassan Pourseyed
Journal:  Iran J Basic Med Sci       Date:  2013-03       Impact factor: 2.699

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.